Mylan Receives Approval for Tramadol Hydrochloride Tablets

Business Wire, June 21, 2002

Business and Health Editors

PITTSBURGH--(BUSINESS WIRE)--June 21, 2002

Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Tablets, 50 mg.

Mylan's Tramadol product is the generic version of R.W. Johnson Pharmaceutical Research Institute's Ultram(R) Tablets which is indicated for the management of moderate to moderately severe pain.

Mylan Laboratories Inc., is a leading pharmaceutical company that develops, manufacturers and markets generic and proprietary prescription pharmaceutical products. The company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through Bertek Pharmaceuticals Inc. For more information, visit www.mylan.com.

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking statements regarding our anticipated financial results and estimates, business prospects and products in research and under going development, all of which involve substantial risks and uncertainties. Such risks and uncertainties are not predictable or quantifiable; consequently, should known or unknown risks or uncertainties materialize, or should our assumptions or estimates prove inaccurate, actual results could differ materially from those expressed or implied by such forward-looking statement. For further details and a discussion of such risks and uncertainties, we encourage you to read Forward-looking Statements found in our Annual Report on Form 10-K for the fiscal year ended March 31, 2001, and in our periodic reports on Forms 10-Q and 8-K (if any).

We assume no obligation to update any forward-looking statements presented here today, whether as a result of new information, future events or otherwise.